Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis.
Sci Rep. 2023 Feb 1;13(1):1816. doi: 10.1038/s41598-023-28907-3.
Sci Rep. 2023.
PMID: 36725872
Free PMC article.